A detailed history of Morgan Stanley transactions in Castle Biosciences Inc stock. As of the latest transaction made, Morgan Stanley holds 650,711 shares of CSTL stock, worth $14.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
650,711
Previous 478,035 36.12%
Holding current value
$14.2 Million
Previous $10.3 Million 39.73%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$18.06 - $25.3 $3.12 Million - $4.37 Million
172,676 Added 36.12%
650,711 $14.4 Million
Q4 2023

Feb 13, 2024

BUY
$12.19 - $22.43 $5.36 Million - $9.86 Million
439,389 Added 1136.96%
478,035 $10.3 Million
Q3 2023

Nov 15, 2023

SELL
$13.28 - $20.3 $878,259 - $1.34 Million
-66,134 Reduced 63.12%
38,646 $652,000
Q2 2023

Aug 14, 2023

BUY
$11.66 - $26.0 $185,580 - $413,816
15,916 Added 17.91%
104,780 $1.44 Million
Q1 2023

May 15, 2023

BUY
$19.47 - $28.49 $594,730 - $870,255
30,546 Added 52.38%
88,864 $2.02 Million
Q4 2022

Feb 14, 2023

SELL
$18.08 - $30.0 $2.49 Million - $4.12 Million
-137,484 Reduced 70.22%
58,318 $1.37 Million
Q3 2022

Nov 14, 2022

BUY
$22.51 - $34.32 $1.96 Million - $2.98 Million
86,863 Added 79.74%
195,802 $5.11 Million
Q2 2022

Oct 27, 2022

BUY
$16.0 - $45.99 $1.31 Million - $3.76 Million
81,797 Added 301.37%
108,939 $2.39 Million
Q2 2022

Aug 15, 2022

BUY
$16.0 - $45.99 $1.31 Million - $3.76 Million
81,797 Added 301.37%
108,939 $2.39 Million
Q1 2022

Oct 27, 2022

SELL
$33.17 - $46.98 $2.71 Million - $3.84 Million
-81,797 Reduced 75.09%
27,142 $1.22 Million
Q1 2022

May 13, 2022

SELL
$33.17 - $46.98 $522,659 - $740,263
-15,757 Reduced 36.73%
27,142 $1.22 Million
Q4 2021

Feb 14, 2022

SELL
$39.06 - $67.58 $1.05 Million - $1.82 Million
-26,923 Reduced 38.56%
42,899 $1.84 Million
Q3 2021

Nov 15, 2021

BUY
$60.13 - $77.6 $4.2 Million - $5.42 Million
69,822 New
69,822 $4.64 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $572M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.